



(11)

**EP 3 406 242 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:  
**Corrected version no 1 (W1 B1)**  
**Corrections, see**  
**Bibliography INID code(s) 54**

(48) Corrigendum issued on:  
**12.07.2023 Bulletin 2023/28**

(45) Date of publication and mention  
of the grant of the patent:  
**07.06.2023 Bulletin 2023/23**

(21) Application number: **18180517.7**

(22) Date of filing: **17.08.2011**

(51) International Patent Classification (IPC):  
**A61K 31/00** <sup>(2006.01)</sup> **A61K 38/04** <sup>(2006.01)</sup>  
**A61P 1/16** <sup>(2006.01)</sup> **A61P 13/12** <sup>(2006.01)</sup>

(52) Cooperative Patent Classification (CPC):  
**A61K 38/10; A61K 38/04; A61P 1/16; A61P 13/12;**  
**G01N 33/6893; G01N 2333/705; G01N 2500/00;**  
**G01N 2800/085; G01N 2800/28; G01N 2800/347;**  
**G01N 2800/52**

(54) **TLR4 ANTAGONIST FOR USE IN THE TREATMENT OF INCREASED AMMONIA PLASMA LEVELS**

TLR4 ANTAGONIST ZUR BEHANDLUNG VON ERHÖHTEN PLASMA AMMONIAK WERTEN

ANTAGONISTE DU TLR4 DESTINÉ À ÊTRE UTILISÉ DANS LE TRAITEMENT DE  
L'AUGMENTATION DES TAUX PLASMATIQUES D'AMMONIAC

(84) Designated Contracting States:  
**AL AT BE BG CH CY CZ DE DK EE ES FI FR GB**  
**GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO**  
**PL PT RO RS SE SI SK SM TR**

(30) Priority: **17.08.2010 GB 201013785**

(43) Date of publication of application:  
**28.11.2018 Bulletin 2018/48**

(62) Document number(s) of the earlier application(s) in  
accordance with Art. 76 EPC:  
**11748969.0 / 2 605 763**

(73) Proprietor: **Yaqrit Limited**  
**Ledbury HR8 1RZ (GB)**

(72) Inventors:  
• **JALAN, Rajiv**  
**Chislehurst, BR7 5EP (GB)**  
• **SHAH, Naina**  
**Croydon, CR0 6QF (GB)**

(74) Representative: **J A Kemp LLP**  
**80 Turnmill Street**  
**London EC1M 5QU (GB)**

(56) References cited:  
• **KITAZAWA TOSHIYUKI ET AL: "Therapeutic approach to regulate innate immune response by Toll-like receptor 4 antagonist E5564 in rats with D-galactosamine-induced acute severe liver injury", JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, WILEY INTERSCIENCE, MELBOURNE, AU, vol. 24, no. 6, 1 June 2009 (2009-06-01), pages 1089-1094, XP009152110, ISSN: 0815-9319, DOI: 10.1111/J.1440-1746.2008.05770.X [retrieved on 2009-02-15]**  
• **CUNNINGHAM PATRICK N ET AL: "Role of toll-like receptor 4 in endotoxin-induced acute renal failure.", JOURNAL OF IMMUNOLOGY, vol. 172, no. 4, 15 February 2004 (2004-02-15), pages 2629-2635, XP009152192, ISSN: 0022-1767**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

**EP 3 406 242 B8**

- **ZAGER RICHARD A ET AL: "Toll-like receptor (TLR4) shedding and depletion: acute proximal tubular cell responses to hypoxic and toxic injury", AMERICAN JOURNAL OF PHYSIOLOGY: RENAL PHYSIOLOGY, AMERICAN PHYSIOLOGICAL SOCIETY, UNITED STATES, vol. 292, no. 1, 1 January 2007 (2007-01-01), pages F304-F312, XP009152133, ISSN: 1931-857X, DOI: 10.1152/AJPRENAL.00237.2006 [retrieved on 2006-08-01]**
- **SEKI EKIHIRO ET AL: "TLR4 mediates inflammation and fibrogenesis after bile duct ligation", HEPATOLOGY, WILLIAMS AND WILKINS, BALTIMORE, MD, US, vol. 42, no. 4, Suppl. 1, 1 October 2005 (2005-10-01), pages 265A-266A, XP009152038, ISSN: 0270-9139 [retrieved on 2005-10-05]**